Evidence map›Paper›PMID 29362919›Full record

ArticleJournal of cancer research and clinical oncology2018

Proliferation-associated miRNAs-494, -205, -21 and -126 detected by in situ hybridization: expression and prognostic potential in breast carcinoma patients.

Natalia Gurvits, Tuomo-Artturi Autere, Heli Repo, Marjukka Nykänen, Teijo Kuopio, Pauliina Kronqvist, Kati Talvinen

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Natalia GurvitsDepartment of Pathology, Turku University Hospital, and Institute of Biomedicine, University of Turku, Turku, Finland. natalia.gurvits@utu.fi.ORCID http://orcid.org/0000-0003-0550-3064
Tuomo-Artturi AutereDepartment of Pathology, Turku University Hospital, and Institute of Biomedicine, University of Turku, Turku, Finland.
Heli RepoDepartment of Pathology, Turku University Hospital, and Institute of Biomedicine, University of Turku, Turku, Finland.
Marjukka NykänenDepartment of Pathology, Central Hospital of Central Finland, Jyväskylä, Finland.
Teijo KuopioBiological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland.
Pauliina KronqvistDepartment of Pathology, Turku University Hospital, and Institute of Biomedicine, University of Turku, Turku, Finland.
Kati TalvinenDepartment of Pathology, Turku University Hospital, and Institute of Biomedicine, University of Turku, Turku, Finland.
University of Turku · FICentral Finland Health Care District · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo visualize by in situ hybridization (ISH) the levels of a set of proliferation-associated miRNAs and to evaluate their impact and clinical applicability in prognostication of invasive breast carcinoma.

methodsTissue specimen from breast carcinoma patients were investigated for miRNAs-494, -205, -21 and -126. Prognostic associations for levels of miRNAs were analyzed based on complete clinical data and up to 22.5-year follow-up of the patient material (n = 285). For detection of the miRNAs, an automated sensitive protocol applying in situ hybridization was developed.

resultsMiRNA-494 indicated prognostic value for patients with invasive breast carcinoma. Among node-negative disease reduced level of miRNA-494 predicted 8.5-fold risk of breast cancer death (p = 0.04). Altered levels and expression patterns of the studied miRNAs were observed in breast carcinomas as compared to benign breast tissue.

conclusionsThe present paper reports for the first time on the prognostic value of miRNA-494 in invasive breast cancer. Particularly, detection of miRNA-494 could benefit patients with node-negative breast cancer in identifying subgroups with aggressive disease. Based on our experience, the developed automatic ISH method to visualize altered levels of miRNAs-494, -205, -21 and -126 could be applied to routine pathology diagnostics providing that conditions of tissue treatment, especially fixation delays, are managed.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCell ProliferationFemaleHumansIn Situ HybridizationMicroRNAsMiddle AgedPrognosisMicroRNAsBreast cancerCell cyclemiRNANode-negativePrognosisProliferation

Identifiers

PMID29362919
PMCPMC11813412
OpenAlexW2784462716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.